Solution Loaded with Alpha-Emitter Radionuclides

Patent metadata

Field	Value
Publication number	US-2025339572-A1
Application number	US-202519269157-A
Country	US
Kind code	A1
Filing date	Jul 15, 2025
Priority date	Jan 16, 2023
Publication date	Nov 6, 2025
Grant date	—

Abstract

A method of generating an emulsion for treating a patient. The method includes generating a water-based solution carrying an agent which turns into a hydrogel by addition of calcium ions. Radium radionuclides are added to the water-based solution in a concentration sufficient for radiotherapy. After adding the radium to the water-based solution, the water-based solution is mixed with an emulsifier and an oil.

First claim

1 . A method of generating an emulsion for treating a patient, comprising:
generating a water-based solution carrying an agent which turns into a hydrogel by addition of calcium ions; adding radium radionuclides to the water-based solution in a concentration sufficient for radiotherapy; and mixing the water-based solution with an emulsifier and an oil, after adding the radium to the water-based solution.

2 . The method of claim 1 , wherein the emulsifier with the oil are of a volume greater than the volume of the water-based solution.

3 . The method of claim 1 , wherein the agent which turns into a hydrogel by addition of calcium ions is between 0.5-4% of the water-based solution.

4 . The method as in claim 3 , wherein the agent which turns into a hydrogel by addition of calcium ions is between 1.2-2.4% of the water-based solution.

5 . The method as in claim 1 , wherein the emulsifier and oil form less than 80% of the emulsion.

6 . The method as in claim 1 , wherein the emulsifier and oil form at least 75% of the emulsion.

7 . The method as in claim 1 , wherein the emulsifier with the oil is Incomplete Freund's Adjuvant (IFA) or Complete Freund's Adjuvant (CFA).

8 . The method as in claim 1 , wherein the oil comprises squalene.

9 . The method as in claim 1 , wherein the mixture further comprises CpG-1018 or monophosphoryl lipid A (MPL).

10 . The method as in claim 1 , wherein the emulsion does not include targeting elements which make the emulsion suitable for targeted therapy.

11 . The method as in claim 1 , further comprising adding to the water-based solution an immune-checkpoint inhibitor.

12 . The method as in claim 1 , further comprising adding to the water-based solution an immunoadjuvant.

13 . The method as in claim 1 , further comprising adding a mycobacterium to the water-based solution.

14 . The method as in claim 1 , further comprising adding a DNA or RNA viral mimic to the water-based solution.

15 . The method as in claim 1 , further comprising adding a tumor antigen to the water-based solution.

16 . The method as in claim 1 , wherein the agent comprises alginate.

17 . The method as in claim 1 , wherein the radium radionuclides are radium-224 radionuclides.

18 . The method as in claim 1 , wherein the emulsion:
does not include calcium; or does not include a sufficient amount of calcium for turning the agent into a hydrogel.

19 . The method of claim 1 , wherein generating the water-based solution comprises dispersing the agent homogenously in the water-based solution.

20 . The method of claim 1 , wherein mixing the water-based solution with an emulsifier and an oil is performed in a syringe suitable for injecting the emulsion to the patient.

21 . A medicament for treating a tumor, comprising:
an agent which turns into a hydrogel by addition of calcium ions; a water-based solution carrying the agent in a manner allowing injection of the medicament into a patient; an emulsifier; an oil; and radium radionuclides bounded to the agent in a concentration sufficient to treat the tumor by radiotherapy.

22 . The medicament as in claim 21 , wherein the agent is dispersed homogenously in the water-based solution.

23 . The medicament as in claim 21 , wherein the medicament does not include targeting elements sufficient for targeted therapy of the medicament.

24 . The medicament as in claim 21 , further comprising a substance which regulates immune-checkpoints dispersed in the medicament.

25 . The medicament as in claim 21 , further comprising an immunoadjuvant.

Assignees

• Alpha Tau Medical Ltd

Inventors

• Domankevich Vered
• Schmidt Michael
• Kelson Itzhak
• Arazi Lior
• Segal Ronen
• Gat Amnon
• Levy Dor

Classifications

• A61K51/1213

  Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature · CPC title

• A61K47/36

  Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin · CPC title

• A61K9/107

  Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)} · CPC title

• A61K9/0024

  Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L) · CPC title

• A61P35/00

  Antineoplastic agents · CPC title